Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.
| Revenue (TTM) | $4.00B |
| Gross Profit (TTM) | $1.38B |
| EBITDA | $849.12M |
| Operating Margin | 15.10% |
| Return on Equity | -7.52% |
| Return on Assets | 4.11% |
| Revenue/Share (TTM) | $81.86 |
| Book Value | $59.50 |
| Price-to-Book | 4.66 |
| Price-to-Sales (TTM) | 3.62 |
| EV/Revenue | 4.02 |
| EV/EBITDA | 72.91 |
| Quarterly Earnings Growth (YoY) | -17.30% |
| Quarterly Revenue Growth (YoY) | -2.70% |
| Shares Outstanding | $48.17M |
| Float | $47.20M |
| % Insiders | 0.47% |
| % Institutions | 123.00% |
Volatility is currently expanding
Investors interested in Medical Services stocks are likely familiar with Progyny (PGNY) and Charles River Laboratories (CRL). But which of these two companies is the best option for those looking for undervalued stocks?
CRL shares have surged 75.8% in a year as RMS trends improve, AI-enabled testing expands and cash flow supports buybacks and investment.
WILMINGTON, Mass. & LONDON--(BUSINESS WIRE)---- $CRL #DrugDiscover--Charles River Laboratories International, Inc. (NYSE: CRL) and Autolomous today announced the launch of Apollo Orchestrate™, a new capability within Charles River's Apollo® platform that connects and digitizes laboratory execution, built on Autolomous's autoloMATE® digital Laboratory Execution System (LES). The launch demonstrates continued progress on Charles River's strategic commitment to modernize and digitize laboratory workflows. Apollo® Orches.
Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day Transcript
Investors looking for stocks in the Medical Services sector might want to consider either Progyny (PGNY) or Charles River Laboratories (CRL). But which of these two stocks presents investors with the better value opportunity right now?
Charles River Laboratories International, Inc. (CRL) Presents at 2026 Global Healthcare Conference Transcript
Charles River Laboratories International, Inc. (CRL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Morgan Stanley and Baird Conferences.
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CRL and any ticker you trade — then tracks every position and per-strategy win rate.
